On Friday, June 13, 2025, co‑founder and former CEO Anne Wojcicki’s nonprofit, TTAM Research Institute, won a court‑approved bankruptcy auction to acquire substantially all of 23andMe’s assets for $305 million — outbidding Regeneron Pharmaceuticals in what may be the company’s final lifeline. In a sea of setbacks, it was a rare moment of hope; a chance for the company to return to its original promise under the guidance of someone who helped define it.
Continue Reading on Medium